City of Hope Hosts Second California Institute for Regenerative Medicine Alpha Stem Cell Clinics Symposium – Business Wire (press release)

DUARTE, Calif.--(BUSINESS WIRE)--The stories of patients who have benefited from stem cell therapies funded by the California Institute for Regenerative Medicine (CIRM) will be highlighted at the second symposium of the institutes Alpha Stem Cell Clinics Network on Thursday, March 23, at City of Hope.

CIRM, the states stem cell agency, has developed a network of Alpha Stem Cell Clinics that are focused on innovative stem cell-based therapies. The network, which consists of three clinics located at City of Hope, UCSD, and UCLA/UC Irvine, will showcase its most successful clinical trials at the daylong symposium.

Scientists, clinicians, patient advocates, and business and insurance experts, as well as CIRM and City of Hope representatives, are hosting the meeting to address various aspects of making more stem cell therapies a reality for patients.

CIRMs Alpha Clinics are working day in and day out to find cures for such debilitating diseases as glioblastoma, leukemia and other cancers, as well as blinding eye diseases, spinal cord injuries, HIV, hemophilia, diabetes and other catastrophic conditions for which there are no current cures, said John A. Zaia, M.D., the Aaron D. Miller and Edith Miller Chair in Gene Therapy, who is also director of the Center for Gene Therapy and principal investigator of City of Hopes Alpha Stem Cell Clinic. This symposium brings us together to share the advancements weve made in delivering stem cell treatments to patients, and to discuss how we can accelerate their development.

Highlights of Alpha Clinics: Making the Future a Reality for Stem Cell-Based Therapies

Registration starts at 7 a.m. There will be a welcome address at 8 a.m. with panels concluding at 5 p.m. View the schedule here.

About City of Hope

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 47 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with communityclinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bonemarrowtransplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Visit link:
City of Hope Hosts Second California Institute for Regenerative Medicine Alpha Stem Cell Clinics Symposium - Business Wire (press release)

The tip of the iceberg: A look at stem cell science at Stanford – Scope (blog)

For outsiders, its easy to get confused about the status of stem cell science. If you have questions, a recentStanford Magazine article offers a reader-friendlyentre.

The piece introduces the pioneering work of Irving Weissman, MD, who was the first researcher to isolate stem cells from adult tissue. And it highlights the amazing outcomefrom a recent clinic trial on stem cell therapy for stroke led by neurosurgeonGary Steinberg, MD, PhD. One woman who used a wheelchair often before the procedure no longer needed it following the procedure. As Steinberg saidin the article:

This was a huge surprise We thought the circuits were dead or irreversibly injured, but theyre clearly not; they can be resurrected. Were still trying to figure out exactly how we are resurrecting them.

Maria Grazia Roncarolo, MD, co-director of theInstitute of Stem Cell Biology and Regenerative Medicine, is one of the researchers working to bring the innovative basic science work taking place at Stanford into the clinic.

My mission is to help the university to build a brand in stem cell therapy, sheexplained. What we are now pushing into the clinic is just the tip of the iceberg But what we really want to build is a translational research program that would allow all the potential stem cell therapies to surface and be offered to patients in need.

Previously: Stem cells create faithful replicas of native tissue, according to Stanford study, Stroke of luck: Stem-cell transplants show strong signs of efficacy in clinical safety trial for strokeand Stanford scientists describe stem-cell and gene-therapy advances in scientific symposium Image by Ghanson

Originally posted here:
The tip of the iceberg: A look at stem cell science at Stanford - Scope (blog)

US Stem Cell Inc (OTCMKTS:USRM) Finding Support After … – Street Register

Shares of US Stem Cell Inc (OTCMKTS:USRM) began to stabilize this week on the heels of a rather large consolidation that affected the stock over a period of several trading days following its huge February price explosion.

From February 1st to March 1st, USRM shares traded from a low of .0024 all the way up to .0599, which represents a dizzying increase of 2395% while volume during that same period was as high as it had ever been over the life of the stock. In the week to follow, USRM would see an unsurprising pull back off of that impressive high, and appears to have found support for the time being.

US Stem Cell Inc (OTCMKTS:USRM) published a PR earlier in the week alluding to the appointment of a new board member- one who had a preexisting relationship with the company. You can read more about that appointment further down the page.

About US Stem Cell

US Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. It is focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The companys business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from the businesses will, over time, provide funds to support clinical development activities. The company believes the combination of its own therapeutics pipeline combined with its revenue generating capabilities provides a unique opportunity for growth and a pathway to profitability.

US Stem Cell Appoints New Board Member

This week, the US Stem Cell announced that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors of U.S. Stem Cell, Inc.

We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments, said Mike Tomas, President and CEO of U.S. Stem Cell, Inc.

A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization. During his entrepreneurial career, Knutson founded Concrete Specialists, Inc. and continues to serve as its President; is the founder and current President of Sunwood Properties; and is the founder and Managing Partner of G&G Land Development, LLC.

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStars preferred shares. (Source: Accesswire)

On a clear downside, USRM has a miniscule market value of just $1.6 million at current pricing. That being said, the sheer intensity of the mega-run we witnessed in February and the fact that the PPS appears to be stabilizing after a large consolidation, is enough to keep our interest. At whatever point the stock ultimately launches a solid recovery, there will almost certainly be opportunities opening up for traders. Were going to continue to track USRM and its progress on the chart, and keep a sharp eye out for new updates. Stay up to date on USRM right here on Street Register. We encourage you to sign up for our 100% free penny stock newsletter, by simply submitting your active email address in the box

Visit link:
US Stem Cell Inc (OTCMKTS:USRM) Finding Support After ... - Street Register

Greg Knutson Joins US Stem Cell, Inc.’s Board of Directors – Yahoo Finance

SUNRISE, FL / ACCESSWIRE / March 7, 2017 / U.S. Stem Cell, Inc., (USRM) a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors of U.S. Stem Cell, Inc.

"We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments," said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization. During his entrepreneurial career, Knutson founded Concrete Specialists, Inc. and continues to serve as its President; is the founder and current President of Sunwood Properties; and is the founder and Managing Partner of G&G Land Development, LLC.

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStar's preferred shares.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Media Contact:

U.S. Stem Cell, Inc. 13794 NW 4th Street, Suite 212 Sunrise, Fl 33325 Phone: 954.835.1500 Email: usstemcell@us-stemcell.com

Read More

SOURCE: U.S. Stem Cell, Inc.

The rest is here:
Greg Knutson Joins US Stem Cell, Inc.'s Board of Directors - Yahoo Finance

Sanford Health invests up to $20M in stem cell device company – MedCity News

MedCity News

Sanford Health invests up to $20M in stem cell device company MedCity News ... adipose-derived stem cells. In a separate call, Rich Adcock, chief innovation officer for Sanford Health, said his organization has a progressive research agenda that goes above and beyond patient care. With some 45 hospitals and nearly 300 clinics ... and more »

Excerpt from:
Sanford Health invests up to $20M in stem cell device company - MedCity News

Here’s the Story on US Stem Cell Inc (OTCMKTS:USRM) – Oracle … – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) is a micro-cap name thats clearly begun to explode higher in recent days. The company has no clear headline catalyst and no other stem cell stocks are moving at all in recent days. Its a bit of a mystery. However, we can see some clues if we take a closer look at the companys recent headline flow and dig a bit under the surface.

In late January, the companys Chief Scientific Officer, Kristin Comella, published her most recent publication. The piece was titled, Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease. The market reaction was clearly on display. However, the boards seem to suggest something about a lawsuit settlement with a standing issue with Northstar Biotech. It is possible there is something about to break more publicly about a resolution that has some bearing on the prospects for this company. We do not see much out there on it and dont see any clear evidence of promotional activity.

US Stem Cell Inc (OTCMKTS:USRM) trumpets itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function.

U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

Find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

According to company materials, US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development, and commercialization of cell-based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

As noted by the company, the business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities, as they do today for our general business operations. We believe the combination of our own therapeutics pipeline, combined with our revenue generating capabilities, provides the Company with a unique opportunity for growth and a pathway to profitability.

Traders will note above 1000% during the past month in terms of shareholder gains in the name, a rally that has pushed up against longer standing distributive pressure in the stock. However, USRM has evidenced sudden upward volatility on many prior occasions. Furthermore, the stock has seen an influx in interest of late, with the stocks recent average trading volume running exceeding 610% above its longer-run average levels.

At this time, carrying a capital value in the market of $2.1M, US Stem Cellhas a store ($246K) of cash on the books, which compares with about $3.3M in total current liabilities. One should also note that debt has been growing over recent quarters. USRM is pulling in trailing 12-month revenues of $2.7M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 30.9%. We will update the story again soon as developments transpire. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

See more here:
Here's the Story on US Stem Cell Inc (OTCMKTS:USRM) - Oracle ... - The Oracle Dispatch

How to Find the Right Stem Cell Clinic – Good4Utah

Dr. Khan from Wasatch Pain Solutions explained which stem cell clinic you should choose for treatment. Dr Khan is the only Regenexxprovider in Utah and he performs the most scientifically advanced stem cell procedures for spine and orthopedic conditions. While it seems many different clinics offer stem cell procedures, they are different because most are using amniotic fluid from another person, instead of your own bone marrow stem cells.

Amniotic stem cells go through extensive processing (which includes gamma radiation) in order to become safe for injection into a new person. During this process, almost all of the stem cells that were alive have been killed off. So essentially you arent getting any stem cells from these injections, but you are still paying the price. Wasatch Pain Solutions uses bone marrow derived stem cells because research has shown it is the most effective and safe way for treating your injuries.

Regenexx is hands down the best option for orthopedic stem cell procedures in the world. Dont be fooled by pop up clinics using amniotic fluid promoted as stem cell therapy. Contact Dr. Khan at Wasatchpainsolutions.com or give them a call 801-302-2690 to see what the most advanced stem cell and blood platelet treatment options could mean for you.

This story includes sponsored content.

Here is the original post:
How to Find the Right Stem Cell Clinic - Good4Utah

Steenblock Research Institute Announces New Method of Obtaining … – PRUnderground (press release)

The treatment of chronic diseases and medical conditions using a patients own stem cells is an exciting, dynamic area of medicine that is enjoying unprecedented success thanks to a combination of new discoveries and impressive patient responses. Here in the US, over 600 private clinics are doing stem cell therapies, most using stem cells taken from a patients own bone marrow or fat tissue.

Unfortunately, many ailing people are reluctant or unable to undergo the harvesting of bone marrow or fat tissue. With this in mind, physician David Steenblock, president of the nonprofit Steenblock Research Institute (SRI), asked the scientists at his research institute to come up with a way of getting enough stem cells from a patients blood sample to treat their health issues.

The scientists at SRI went on to develop an FDA compliant method for winding up with as many stem cells in 2 small tubes of blood (drawn from a patient) as are normally obtained from much larger quantities of bone marrow or fat tissue. The blood is exposed to heat, cold, light and electromagnetics which yields 100 million stem cells, an amount which is ten times the minimum of 10 million cells needed to produce a clinical response.

SRIs new method has beenauthorized for use byonly one clinic: Personalized Regenerative Medicine Clinic of San Clemente, California.

Adds Dr. Steenblock, Stem Cell Therapy is experimental and thus is not covered by any insurance plan. This new method is also only available to patients of Personalized Regenerative Medicine Clinic.

Those interested in learning more are invited to call Personalized Regenerative Medicine Clinic (PRMC) at 1-949-367-8870 from 9 am to 4 pm Pacific Time, Monday through Friday. Individuals who enroll as new patients are being offered an initial office visit for free with PRMCs Dr. Donna Hanna.

About David A. Steenblock, D.O., Inc.

Dr. David Steenblock and his Personalized Regenerative Medicine Clinic are both committed to and passionate about advancing medicine. They do this, in part, by creating customized treatment regimens for patients which often includes the use of stem cells and FDA approved stem cell mobilizers and activators. In addition, Dr. Steenblock brings to the table finely honed diagnostic skills as well as a wealth of knowledge, experience, and insight plus the courage to explore, experiment and innovate in a private clinical setting.

The rest is here:
Steenblock Research Institute Announces New Method of Obtaining ... - PRUnderground (press release)

R3 Stem Cell Now Offering Regenerative Medicine Treatment in … – PR Web (press release)

Top Stem Cell Therapy in Oklahoma City (844) GET-STEM

Oklahoma City, Oklahoma (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Oklahoma City with a new Center of Excellence. R3 has partnered with Venturis Clinic, who offers stem cell and PRP therapy along with prolozone treatment by the Board Certified doctors. Call (844) GET-STEM for more information and scheduling.

Stem cell therapy is now mainstream, and helps individuals every day avoid the need for possibly risky surgery. It's helping athletes get back on the field faster, avoid joint replacement and finally achieve pain relief with chronic tendonitis conditions. The regenerative treatments are offered by a Board Certified provider in a contemporary setting.

The stem cell and PRP therapy in Oklahoma City are all outpatient with absolutely minimal risk. Unlike cortisone injections, these treatments actually repair and regenerate cartilage, muscle, bone, tendon, ligament and other damaged tissue.

Minimal down time is necessary after the stem cell therapy in Oklahoma City, which is the opposite of traditional surgery. The treatments contain stem cells, growth factors, concentrated platelets, cytokines and hyaluronic acid. The combination makes for an amazing regenerative environment once injected.

To receive cutting edge regenerative treatment, call Venturis Clinic in Oklahoma City which is now an R3 Stem Cell Center of Excellence at (844) GET-STEM. Also visit https://r3stemcell.com for more information.

Share article on social media or email:

Read more here:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in ... - PR Web (press release)

R3 Stem Cell Now Offering Regenerative Medicine Treatment in Oklahoma City – Satellite PR News (press release)

Submit the press release

Top Stem Cell Therapy in Oklahoma City (844) GET-STEM

Over 85% of patients at Venturis achieve excellent outcomes with regenerative medicine treatment for arthritis, tendonitis, back pain and more!

Oklahoma City, Oklahoma (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Oklahoma City with a new Center of Excellence. R3 has partnered with Venturis Clinic, who offers stem cell and PRP therapy along with prolozone treatment by the Board Certified doctors. Call (844) GET-STEM for more information and scheduling.

Stem cell therapy is now mainstream, and helps individuals every day avoid the need for possibly risky surgery. Its helping athletes get back on the field faster, avoid joint replacement and finally achieve pain relief with chronic tendonitis conditions. The regenerative treatments are offered by a Board Certified provider in a contemporary setting.

The stem cell and PRP therapy in Oklahoma City are all outpatient with absolutely minimal risk. Unlike cortisone injections, these treatments actually repair and regenerate cartilage, muscle, bone, tendon, ligament and other damaged tissue.

Minimal down time is necessary after the stem cell therapy in Oklahoma City, which is the opposite of traditional surgery. The treatments contain stem cells, growth factors, concentrated platelets, cytokines and hyaluronic acid. The combination makes for an amazing regenerative environment once injected.

To receive cutting edge regenerative treatment, call Venturis Clinic in Oklahoma City which is now an R3 Stem Cell Center of Excellence at (844) GET-STEM. Also visit https://r3stemcell.com for more information.

Share article on social media or email:

Read the original:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in Oklahoma City - Satellite PR News (press release)